192 related articles for article (PubMed ID: 20145159)
21. Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.
Duan H; Lu J; Lu T; Gao J; Zhang J; Xu Y; Wang M; Wu H; Liang Z; Liu T
Int J Clin Exp Pathol; 2015; 8(10):13136-45. PubMed ID: 26722512
[TBL] [Abstract][Full Text] [Related]
22. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.
Del Re M; Tiseo M; Bordi P; D'Incecco A; Camerini A; Petrini I; Lucchesi M; Inno A; Spada D; Vasile E; Citi V; Malpeli G; Testa E; Gori S; Falcone A; Amoroso D; Chella A; Cappuzzo F; Ardizzoni A; Scarpa A; Danesi R
Oncotarget; 2017 Feb; 8(8):13611-13619. PubMed ID: 26799287
[TBL] [Abstract][Full Text] [Related]
23. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease.
Pesek M; Kopeckova M; Benesova L; Meszarosova A; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2011 Dec; 31(12):4647-52. PubMed ID: 22199344
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.
Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y
Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer.
Chen CC; Chiu HH; Yen LC; Chang HJ; Chang MS; Tsai JR; Chen YF; Lin SR
Oncol Rep; 2010 Mar; 23(3):639-45. PubMed ID: 20127001
[TBL] [Abstract][Full Text] [Related]
27. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
[TBL] [Abstract][Full Text] [Related]
28. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
30. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.
Johung KL; Yao X; Li F; Yu JB; Gettinger SN; Goldberg S; Decker RH; Hess JA; Chiang VL; Contessa JN
Clin Cancer Res; 2013 Oct; 19(19):5523-32. PubMed ID: 23897899
[TBL] [Abstract][Full Text] [Related]
31. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
Han JY; Choi JJ; Kim JY; Han YL; Lee GK
BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
Bonanno L; Schiavon M; Nardo G; Bertorelle R; Bonaldi L; Galligioni A; Indraccolo S; Pasello G; Rea F; Favaretto A
Anticancer Res; 2010 Dec; 30(12):5121-8. PubMed ID: 21187500
[TBL] [Abstract][Full Text] [Related]
33. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K; Tomizawa K; Mitsudomi T
Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
[TBL] [Abstract][Full Text] [Related]
34. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer.
Takahashi T; Sonobe M; Menju T; Nakayama E; Mino N; Iwakiri S; Nagai S; Sato K; Miyahara R; Okubo K; Hirata T; Date H; Wada H
J Surg Oncol; 2010 May; 101(6):500-6. PubMed ID: 20213688
[TBL] [Abstract][Full Text] [Related]
35. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
Kim ST; Sung JS; Jo UH; Park KH; Shin SW; Kim YH
Med Oncol; 2013 Mar; 30(1):328. PubMed ID: 23307237
[TBL] [Abstract][Full Text] [Related]
36. Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors.
Leary AF; Castro DG; Nicholson AG; Ashley S; Wotherspoon A; O'Brien ME; Popat S
Eur J Cancer; 2012 Jan; 48(1):61-7. PubMed ID: 22036089
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor mutation in gastric cancer.
Liu Z; Liu L; Li M; Wang Z; Feng L; Zhang Q; Cheng S; Lu S
Pathology; 2011 Apr; 43(3):234-8. PubMed ID: 21436633
[TBL] [Abstract][Full Text] [Related]
39. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients.
Tsao DA; Yang MJ; Chang HJ; Yen LC; Chiu HH; Hsueh EJ; Chen YF; Lin SR
Lung Cancer; 2010 Apr; 68(1):51-7. PubMed ID: 19589613
[TBL] [Abstract][Full Text] [Related]
40. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
